At Patheon, we have approximately 600 PDS scientists working on more than 300 client development projects in all phases of clinical development and across a full range of molecules and dosage forms.

Patheon has the proven ability and the experience to develop your molecule into a viable dosage form. From Quick to Clinic™ accelerated early phase development programs to late stage Clinical Trial Materials (CTM) manufacturing requirements, Patheon is prepared to deliver results.  This includes the commercialization of important new molecules for our customers.